Know Cancer

or
forgot password

Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents


N/A
12 Years
24 Years
Open (Enrolling)
Both
HPV Infection, Cervical/Anal Dysplasia

Thank you

Trial Information

Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents


Human Papillomavirus (HPV) is the most common sexually transmitted disease and it causes
cervical and anal cancer. Prevalence and incidence of HPV infection among young adults who
are sexually experienced is high. No data exist for HIV-positive adolescents in regards to
HPV infection, cervical and anal intraepithelial neoplasia. This study will compare the
prevalence of HPV infection, intraepithelial neoplasia and E6/E7 biomarker at cervical and
anal sites among perinatally HIV-infected adolescents, behaviorally HIV-infected
adolescents, and HIV-negative adolescents.


Inclusion Criteria:



- Perinatally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic
acid testing (NAT) at any time and history of maternal HIV infection)

- behaviorally-infected (documented positive HIV enzyme immunoassay (EIA) or nucleic
acid testing (NAT) at any time after sexual debut without history of maternal HIV
infection)

- female with vaginal or receptive anal intercourse with a male OR male with receptive
rectal intercourse with another male

- Signed informed consent. Volunteers aged 12-17 years can decide whether they wish for
their parents to consent for their participation. Due to the confidential nature of
the issues being studied, parental consent may be exempted

Exclusion Criteria:

- Have any conditions that may interfer with subjects' ability to understand and
consent to the study

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

HPV infection

Outcome Description:

Prevalence of cervical and anal HPV infection and of oncogenic subtypes, among perinatally HIV-infected adolescents, behaviorally HIV-infected adolescents, and HIv-negative adolescents

Outcome Time Frame:

48 weeks

Safety Issue:

Yes

Principal Investigator

Jintanat Ananworanich, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

The HIV Netherlands Australia Thailand Research Collaboration

Authority:

Thailand: Ethical Committee

Study ID:

HIV-NAT 139

NCT ID:

NCT01788852

Start Date:

December 2010

Completion Date:

December 2013

Related Keywords:

  • HPV Infection
  • Cervical/Anal Dysplasia
  • HPV
  • HIV
  • cervical/anal dysplasia
  • intraepithelial neoplasia
  • E6/E7 biomarker
  • perinatally HIV-infected adolescents
  • behaviorally HIV-infected adolescents
  • anal and pap smear
  • Carcinoma in Situ

Name

Location